sofpironium bromide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 5428 | 1628106-94-4 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Sofpironium bromide gel is a topical anticholinergic agent developed for the treatment of hyperhidrosis. The drug is designed to reduce sweating by inhibiting M3 muscarinic receptors in eccrine glands at the application site.
|
Drug dosage:
None
ADMET properties:
None
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Sept. 25, 2020 | PMDA | Kaken Pharmaceutical |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
None
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Hyperhidrosis | indication | 312230002 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Muscarinic acetylcholine receptor M3 | GPCR | INHIBITOR | SCIENTIFIC LITERATURE | SCIENTIFIC LITERATURE |
External reference:
| ID | Source |
|---|---|
| D10989 | KEGG_DRUG |
| 7B2Y1932XU | UNII |
| 1628251-49-9 | SECONDARY_CAS_RN |
| C4726762 | UMLSCUI |
| CHEMBL3707223 | ChEMBL_ID |
| 86301316 | PUBCHEM_CID |
| CHEMBL3707224 | ChEMBL_ID |
| 10398 | INN_ID |
Pharmaceutical products:
None